<div id="subtitle">Vical says US approves Oncept dog vaccine, which will be marketed by Sanofi-Aventis</div><div><p>Drug developer Vical Inc. said Monday the Agriculture Department approved Oncept, a vaccine intended to treat oral melanoma in dogs.</p><p>Vical developed the drug and licensed it to Merial Ltd., a division of French drugmaker Sanofi-Aventis. It said Merial plans to launch Oncept at the North American Veterinary Conference, which starts later this week.</p><p>In morning trading, Vical shares rose 12 cents, or 3.5 percent, to $3.57. U.S.-listed shares of Sanofi-Aventis gained 65 cents to $40.84.</p><img src="http://admatch-syndication.mochila.com/images/ad.gif?aid=66702018&bid=informcom" /></div><div id="copyright"><div>

Copyright 2010  <a href="http://www.ap.org">AP News</a></div></div>